Olmesartan Impurity 6

Olmesartan Impurity 6 is a process-related byproduct formed during the synthesis of olmesartan medoxomil via amidation of 4’-chlorobiphenyl-2-carboxylic acid. It retains the biphenyl core but lacks the tetrazole ring, featuring instead a substituted pyridine moiety linked through an amide bond. The compound exhibits a hydroxyl group at the 5-position of the pyridine and a methoxy ester functionality, distinguishing it from the parent drug’s angiotensin II receptor antagonist structure. This impurity arises from premature termination of the tetrazole-forming cascade, serving as a key HPLC reference standard for monitoring synthetic pathway efficiency.